Navigation Links
For some diabetics, burden of care rivals complications of disease
Date:9/26/2007

ather be well on the road to future blindness, kidney failure or amputations then work hard now at their diabetes."

Huang and colleagues conducted hour-long face-to-face interviews with a multiethnic sample of 701 adult, type-2 diabetes patients attending Chicago area clinics between May 2004 and May 2006. They asked patients to rank the benefits of various treatments and the daily quality-of-life burdens of diabetes-associated complications.

Patients were asked to express their preferences in a series of trade-offs. The surveyors asked, for example: would you rather have six years of life in perfect health, or ten years with an amputation"

As expected, patients were most distressed by end-stage complications, especially kidney failure, a major stroke or blindness. They were slightly less concerned about amputations or diabetic retina damage, and still less about angina, diabetic nerve or kidney damage.

Patients also disliked intensive treatments, especially intensive glucose control, with multiple daily insulin injections, and what the authors called comprehensive diabetes care, which was intensive glucose control plus other medications.

On average, patients ranked the burden of comprehensive diabetes care and intensive glucose control as equal to the burden of angina, diabetic nerve damage or kidney damage.

Patients varied widely in how they ranked treatments and complications. Those who had experience with a specific medication or complication saw them as having less of an impact on quality of life than those without such direct experience.

But many patients found both complications and treatment onerous. Between 12 and 50 percent were willing to give up 8 of 10 years of life in perfect health to avoid life with complications. More surprising, between 10 and 18 percent of patients were willing to give up 8 of 10 years of healthy life to avoid life with treatments.

The existing burden of tre
'/>"/>

Contact: John Easton
John.Easton@uchospitals.edu
773-702-6241
University of Chicago Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Burden of lung disease
2. Suggestions to reduce global heart disease burden
3. Poor Health of people in Central Goldfields Shire, reports The Victorian Burden of Disease
4. Study Finds ER Not Overburdened By Uninsured & Immigrants
5. Dementia Care Intervention Eases Burden for Families
6. America Sags Under Burden of Neurological Diseases
7. Increased Depression, Burden, Reported in Family Caregivers of ALS Patients
8. Refugees No Burden On Health System
9. Hospital Infections Like MRSA Affect The New Arrivals More
10. Rivals of the South Dakota Law Says No to Abortion
11. Coronary stent leads to complications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...ural organic atoms with metal complexes, scientist...e of enzyme inhibitor capable of blocking a bioche...lopment. , Based on studies in human melanoma c...w ways to treat cancer by dampening the overactive...growth. , Details of the study, to be published ...
(Date:5/15/2008)...audit of community hospitals associated with Fox C... partnership between a major academic cancer cente... and community hospitals, where most care is provi...ffectively disseminating advances in cancer treatm...ive Cancer Center in Philadelphia, first establish...
(Date:5/15/2008)...he anti-inflammatory medication also known by the ...uces a specific proliferation measurement of preca...from The University of Texas M. D. Anderson Cancer...e of COX-2 inhibition toward preventing lung cance...disease. , The study is the first large randomiz...
(Date:5/15/2008)...re/ -- JumpStart Inc., the Northeast Ohio,venture ...th of innovative,early-stage businesses and ideas,...0 in CerviLenz(TM), Inc. The Cleveland-based compa...inistration cleared medical,device that allows obs...egnant women, which has been established by the Na...
Breaking Medicine News(10 mins):Health News:Novel enzyme inhibitor paves way for new cancer drug 2Health News:Novel enzyme inhibitor paves way for new cancer drug 3Health News:Partnership of academic centers and community hospitals effective model for disseminating advances 2Health News:Partnership of academic centers and community hospitals effective model for disseminating advances 3Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 3Health News:CerviLenz Receives JumpStart Investment 2Health News:CerviLenz Receives JumpStart Investment 3
...rom Georgia Institute of Technology, US and the Jo...h the pathogenic bacteria defends itself from the ...ave reported the results of their research in the ... cause food borne illness by producing toxins in t...
...om Asan medical center has reported in the Journal...ffective in treating emotional stress or emotional...earchers conducted their study in 152 patients who...months and the results found that the study patien...
...nts with breast cancer and adversely affects the l...ished in the January 15 issue of the American Jour...om a Chinese study are identical to conclusions th...udies and ponit to the fact that obesity seems to ...
...jected alarming results that the practice of inter... the risk of contracting HIV virus by a margin of ...ased risk if detergents are used for the same acco...esults of this research can be found in Aids journ...
Other Medicine News:Health News:Increased Risk Of HIV Transmission Following Vaginal Washing 2
(Date:5/15/2008)...A Trial data reports in third quarter ...RNewswire-FirstCall/ -- VIA Pharmaceuticals,Inc. ...on the development of,compounds for the treatment ... has completed patient enrollment in its acute cor...f three Phase 2 trials investigating VIA-2291,the...
(Date:5/15/2008)... Meeting of The American Society of Ped...INE, Calif., May 15 /- IDM ...announced the presentation of updated data,from a ...e (L-MTP-PE) in,patients with lung metastases as a... and often fatal bone tumor that typically affects...
(Date:5/14/2008)...swire-FirstCall/ -- Progen,Pharmaceuticals Limited...Company has resumed patient enrolment in the phase...polyamine analogue, PG-11047 (formerly CGC-11047),...mmenced development of PG-11047 - the lead clinica...llowing its acquisition of,Cellgate, Inc earlier t...
(Date:5/14/2008)...PacificGMP, the leader in utilizing,single-use bio...ts client,partners, announced today that it has co...ng practices) standards for a Trius Therapeutics P...orked closely with Trius on this GMP fill,project,...nd complete,within a narrow deadline," said Leigh ...
Breaking Medicine Technology:VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 2IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 4IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 6Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2PacificGMP Completes GMP Product Fill for Trius Therapeutics 2VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 1094 1VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 1094 2VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 1094 3Grid computing offers new hope in race against bird flu 3001 1Grid computing offers new hope in race against bird flu 3001 2Fungus genome yielding answers to protect grains people and animals 699 1Fungus genome yielding answers to protect grains people and animals 699 2Fungus genome yielding answers to protect grains people and animals 699 3The reservoir of Marburg virus identified in a species of fruit bat 697 1The reservoir of Marburg virus identified in a species of fruit bat 697 2The reservoir of Marburg virus identified in a species of fruit bat 697 3
...ed on Glucose Homeostasis Effects in,Normal and Di...-FirstCall/ -- In a 14-day,Phase IIa study of the...tional compound dapagliflozin, a selective inhibit...inistered alone or,concomitantly with metformin in...s due to adverse events and no serious adverse,eve...
.../PRNewswire/ -- Novagali Pharma, an,emerging pharm...sents positive results of its pivotal phase III cl...linical study of Vekacia(R) in,children suffering ...Afro-Asian Congress of ophthalmology (AACO) held f...KC is a severe form of chronic allergic conjunctiv...
Other Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 2Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 4
Transfuse-ID™, a bedside Transfusion Verification System, is used by hospitals to ensure that a patient receives the specific unit(s) of blood that was typed and crossmatched for them. It has th
...stem helps ensure a safe care environment by autom...he unit dose level. The automated process and reli...ion and handling of all items, including vials, am...reparations and more. This saves valuable time for...
...nsfusion Safety Management system ensures your pat...care. , BloodTrack SafeTx uses the AutoPPI™ b...nt from sample collection to transfusion. SafeTx c...uces the need for bedside paperwork and associated...
wBloodCare™ provides functionality at the bedside to ensure that the correct patient receives the correct blood product.
Medicine Products: